Why Pear Therapeutics Stock Is Rising Today

Pear Therapeutics Inc PEAR is trading higher Monday following positive analyst coverage from BTIG.

BTIG analyst Marie Thibault initiated coverage on Pear Therapeutics with a Buy rating and announced a $12 price target.

Thibault thinks Pear Therapeutics is one of the best-positioned companies in the prescription digital therapeutics space.

The BTIG analyst highlighted the company's PearCreate and PearConnect platforms, saying that the digital platforms give the company a head start from a regulatory, commercial and operational perspective.

See Also: Why Genprex Shares Are Soaring Today

Pear Therapeutics is engaged in developing and commercializing software-based medicines, called prescription digital therapeutics. 

PEAR Price Action: Pear Therapeutics has traded as low as $4.85 and as high as $7.52 over a 52-week period.

The stock was up 25.3% at $7.77 at time of publication.